BRIEF-Radius Health says CHMP has issued second day-180 list of outstanding issues in its regulatory review of Eladynos

* Radius health announces that the committee for medicinal products for human use (chmp) has issued a second day-180 list of outstanding issues in its regulatory review of Eladynos™ (abaloparatide-sc), a bone building agent for the treatment of postmenopausal women with osteoporosis at high risk for fracture